Mantle cell lymphoma management trends and novel agents: where are we going?

The heterogeneity in disease pathology, the unpredictability in disease prognosis, and the variability in response to therapy make mantle cell lymphoma (MCL) a focus of novel therapeutic development. MCL is characterized by dysregulated expression of cyclin D1 through a chromosome t(11;14) translocation. MCL international prognostic index (MIPI), ki-67 proliferation index, and TP53 mutation status are currently utilized for prognostication. With advances in pharmacokinetic analysis and drug discovery, treatment strategy has evolved from chemotherapy to combination of targeted, epigenetic, and immune therapies. In this review, we discuss investigational and newly approved treatment approaches. In a short time, the US Food and Drug Administration (FDA) has approved five agents for the treatment of MCL: lenalidomide, an immunomodulatory agent; bortezomib, a proteasome inhibitor; and ibrutinib, acalabrutinib, and zanubrutinib, all Bruton kinase inhibitors. Epigenetic agents (e.g. cladribine and vorinostat), mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus and everolimus), and monoclonal antibodies and/or antibody-drug conjugates (e.g. obinutuzumab, polatuzumab, and ublituximab) are promising therapeutic agents currently under clinical trial investigation. Most recently, chimeric antigen receptor (CAR)-T cell therapy and bispecific T-cell engager (BiTE) therapy even open a new venue for MCL treatment. However, due to its intricate pathology nature and high relapse incidence, there are still unmet needs in developing optimal therapeutic strategies for both frontline and relapsed/refractory settings. The ultimate goal is to develop innovative personalized combination therapy approaches for the purpose of delivering precision medicine to cure this disease.

Introduction

Mantle cell lymphoma (MCL) is a rare subtype of lymphoid malignancies that accounts for 2.5–6% of all non-Hodgkin lymphomas (NHLs), with an annual incidence of 1 in 200,000 people.[1-3] MCL is more common in men than women (3 to 1), and the median age at diagnosis is between 60 and 70 years of age. To date, MCL remains a largely incurable disease with a median overall survival (OS) of 5 years.

MCL is characterized by a t(11;14)(q13; q32) translocation that places the cyclin D1 (CCND1) gene, located at chromosome 11q13, under the influence of the immunoglobulin heavy chain gene (IGH) enhancers at chromosome 14q32. Thus, MCL pathogenesis is driven by the uncontrolled growth of B cells. Typically undetectable in lymphoid and hematopoietic tissue, CCND1 controls the cells’ transition from G1 to S phase of cell cycle. As the main pathological driver of disease, CCND1 has become a valuable marker for diagnosis and, more recently, treatment of MCL.[6,7] Epigenetic deregulation of cyclin D1 has also been reported to accelerate cell cycle and tumorigenesis. As such, MCL can be regarded as the paradigm of lymphoma with increased proliferation due to a dysregulated cell cycle.

Many factors are involved in the prognostication of MCL, including age, organ involvement, lactate dehydrogenase (LDH) level, leukocyte count, severity of anemia, TP53 gene mutation, Ki-67 proliferation index, and the MCL international prognostic index (MIPI) score.[2,9-12] The MIPI stratifies patients into three risk categories: low, indeterminate, and high. This distinction has helped to provide quantitative prognostic values with regard to mean OS, with the low-risk group conferring a mean OS that has not yet been reached; over 60% of the patients have reached the 5-year survival mark. Meanwhile, the intermediate and high-risk groups reached a median OS of 51 and 29 months, respectively. Efforts have been made to incorporate Ki-67, a MIPI-independent surrogate marker of cellular proliferation, into MCL prognosis stratification. In specific patient populations, including those receiving high-dose chemotherapy and autologous stem cell transplant (ASCT), Ki-67 has been found to be a better predictor of survival than MIPI. In addition, the Ki-67 index has a better predictive value than MIPI in randomized trials of rituximab-containing regimens.

Identifying prognostic values has become more critical with the advent of personalized medicine and the increasing economic feasibility of next-generation sequencing (NGS). On a singular gene basis, specific genes such as Sox 11 were found to be a biomarker predicting response to treatment. However, this approach can also be extended to the entire human genome where gene expression profiling of mRNA extracted from bulk tissue biopsies can be used to correlate with clinical outcomes. TP53 mutations and CDKN2A deletion demonstrated a significant association with inferior clinical outcomes. Multivariate analysis further found that harboring TP53 mutations correlated significantly with other adverse risk features. Median progression-free survival (PFS) among patients harboring a TP53 mutation was 1 year, whereas those without a TP53 mutation achieved a median PFS of 12.7 years.[16,17] Generally, patients with TP53 mutation do poorly with conventional therapy and consequently require alternative novel therapeutic approaches. More recently, the long-term follow-up data from patients enrolled in the Nordic Mantle Cell Lymphoma Trials, MCL2 and MCL3, demonstrated that patients with progression of disease before 24 months (POD24, n = 51, 34%) displayed a median OS of 6.6 months compared with 46 months for patients with later POD (n = 98, 66%; P < 0.001), which confirmed that POD24 is a novel biomarker for MCL death-risk stratification.[18,19]

In this review, we discuss a multitude of novel therapeutic agents and strategies that have evolved in recent years, including bortezomib, Bruton’s tyrosine kinase (BTK) inhibitors, lenalidomide and other immunomodulatory agents, venetoclax, advances in ASCT, chimeric antigen receptor (CAR)-T cell, and bispecific T-cell engager (BiTE) therapies (Figure 1). We also discuss some promising novel molecules in evaluation.

Figure 1.

MCL treatment algorithm.

BiTE, bispecific T-cell engager; BR, bendamustine and rituximab; BTK, Bruton’s tyrosine kinase; CAR-T, chimeric antigen receptor-T cell; CHOP, cyclophosphamide, vincristine, doxorubicin, and prednisone; Mod, modified; mTOR, mammalian target of rapamycin; RDHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-HyperCVAD, rituximab in combination with hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone; V, bortezomib; VcR-CVAD, bortezomib with modified R-HyperCVAD; VR-CAP, bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone.

Efficacy of novel agents

With the advancement in developing innovative MCL therapies, the treatment paradigm is constantly evolving. From optimizing traditional methods by implementing new or repurposed drugs such as bortezomib or ibrutinib and other BTK inhibitors to the advent of novel approaches, including the advance of CAR-T cell therapy and BiTE therapy strategies, the field of MCL therapy has expanded into a wide variety of novel therapeutics in development. Alternatively, the traditional ASCT, with the purpose of prolonging remission, is also evolving. Autologous tumor cell vaccine study found that activation of CpG motif in tumor cells can enhance tumor responses and significantly impact the disease course.

Bortezomib

Bortezomib, a first-generation proteasome inhibitor, has seen limited efficacy in response rates in relapsed MCL patients as a monotherapy. In combination settings with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), bortezomib demonstrated an overall response rate (ORR) of 81–91%, complete response (CR) of 64%, and a median PFS of 23 months. Vincristine was removed in that protocol due to neurotoxicity. A combination of bortezomib and R-CHP could accomplish a better median PFS than R-CHOP of 24.7 versus 14.4 months, respectively. Initiating bortezomib as post-bortezomib-R-CHP treatment maintenance therapy could further enhance CR and PFS to 83% and 29.5 months, respectively. However, patients usually do not tolerate bortezomib maintenance well due to neuro- and gastrointestinal toxicities.

Bortezomib has been shown to be safe in combination with intensive regimens such as R-HyperCVAD (rituximab in combination with hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone alternating with rituximab-methotrexate and cytarabine). The addition of bortezomib to modified R-HyperCVAD or VcR-CVAD (bortezomib with modified R-HyperCVAD) made long-term remission possible, with ORR of 95% and CR of 68%. Post-induction comparison between 2 years of rituximab maintenance and ASCT showed similar OS and PFS. Wisconsin Oncology Network analyzed long-term follow-up data after VcR-CVAD induction regimen and rituximab maintenance for 5 years, in which ORR and CR were 90% and 77%, respectively. The median PFS was 8.14 years and its OS was still not yet reached at the time of analysis. A post-ASCT bortezomib and rituximab (BR) treatment study found a 2-year disease-free survival (DFS) and OS of 94.4% and 100%, respectively. Currently, several clinical trials combining a second-generation oral proteasome inhibitor, Ixazomib, with other immunotherapy regimens and target therapy regimens in treating MCL are ongoing (https://clinicaltrials.gov; Table 1).

Table 1.

The ongoing clinical trials combining Ixazomib with other immunotherapy regimens and target therapy regimens in treating MCL.

Trial phase	Setting	ClinicalTrials.gov identifier	Study titles
1/2	Relapsed/refractory MCL	NCT03323151	A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
2	BTK inhibitor-resistant MCL	NCT04047797	Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
1/2	Post-autologous HSC transplant in MCL	NCT02632396	Ixazomib & Rituximab after Stem Cell Transplant in Treating Patients with Mantle Cell Lymphoma in Remission
2	Indolent B-cell NHL	NCT02339922	Ixazomib Citrate and Rituximab in Treating Patients with Indolent B-Cell Non-Hodgkin Lymphoma
2	Post-treatment maintenance therapy	NCT03616782	Ixazomib Maintenance in Patients with Newly Diagnosed Mantle Cell Lymphoma (MCL)

BTK, Bruton’s tyrosine kinase; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma.

In an 128 clinical centers participated open-label phase III study, the efficacy of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP), and R-CHOP were compared among 487 transplant-ineligible MCL patients. The median OS for patients who received VR-CAP was significantly longer than for patients who received R-CHOP, 90.7 versus 55.7 months, with a manageable toxicity profile.

Ibrutinib and other BTK inhibitors

Ibrutinib is the US Food and Drug Administration (FDA)–approved original first-in-class BTK inhibitor preferred for relapsed/refractory (R/R) MCL in the standard care setting. The initial response rate and CR rates were 77% and 33%, respectively. For R/R MCL, ibrutinib could only achieve a CR of 26.5% with a median PFS of 13 months. In contrast, among the patients with one prior line of chemotherapy, the median PFS increased to 33.6 months and median OS to 26.7 months.

Rule et al. conducted a pooled analysis and reported a 3.5-year follow-up data of 370 patients with R/R MCL who received ibrutinib 560 mg once daily from 2011 to 2013. They found that patients who received second-line ibrutinib treatment and achieved CR would benefit most from ibrutinib without significant long-term toxicity. Similarly, this group also reported the results from the final analysis of an extended 38.7 months follow-up data from a randomized, open-label phase III RAY study that evaluated the efficacy and safety of ibrutinib compared with temsirolimus. At this extended follow-up study, 33 patients remained in the ibrutinib group, and there were no crossover patients from the temsirolimus group to the ibrutinib group. Median PFS was significantly greater in the ibrutinib cohort than the temsirolimus cohort [15.6 versus 6.2 months; hazard ratio, HR = 0.45 (95% confidence interval, CI = 0.35–0.60); P < 0.0001]. Longer PFS was noted in ibrutinib cohort regardless of the number of prior lines of therapy.

Combination of ibrutinib with rituximab (IR) was also explored in relapsed MCL. Jain et al. conducted the first single-center phase II clinical trial to analyze the efficacy and safety of IR combination as the first-line treatment for elderly MCL patients. With a median age of 71 years old, eastern cooperative oncology group (ECOG) performance score of 0–1 in 98% of the cohort, and a median number of IR cycles of 19, the best ORR was 95% (69% CR, 26% PR, 5% stable disease). Moreover, 65% achieved minimal residual disease (MRD) negative CR by flow cytometry. Predominant grade 3–4 toxicities were myalgia (17%), fatigue (14%), dyspnea (12%), neutropenia (9%), and new-onset atrial fibrillation (5%). Jain et al. also reported the data from a 4-year follow-up of a single-arm, phase II IR trial among patients with R/R MCL. In this study, 58% of patients achieved CR in which 12 patients remained in the study at the time of analysis. High-risk features, such as blastoid morphology, high MIPI score, and high Ki-67, were noted to have inferior survival. This study concluded that IR combination could benefit R/R patients with a durable remission, especially those with low Ki-67.

Dual targets including BTK and B-cell lymphoma-2 (BCL-2) were recently explored in a phase II single-arm trial, in which 23 patients with R/R MCL and 1 with previously untreated MCL received ibrutinib 560 mg per day followed by addition of venetoclax in a stepwise fashion 4 weeks later with a maximum dose of 400 mg once daily. In this study, 62% of patients achieved positron emission tomography (PET) confirmed CR, and 67% reached MRD via flow cytometry. Common adverse events (AEs) were diarrhea, fatigue, and nausea or vomiting in low-grade toxicity range.

Beyond Bruton’s tyrosine kinase inhibitor (BTKi) therapy, Eyre et al. evaluated the efficacy of venetoclax monotherapy in patients with R/R MCL after receiving BTKi therapy. The study evaluated 20 patients whose median prior therapy lines were three, including high-dose cytarabine-based induction regimen (40%) and ASCT in first remission (30%). At first and subsequent relapse, all of them had received BTK inhibitor treatments (17 received ibrutinib). Before receiving venetoclax monotherapy, 95% had stage III/IV disease, 50% were classified as high-risk according to s-MIPI score system, and the median Ki-67 was 45%. In this study, venetoclax monotherapy ORR was 53%, with 18% achieving CR and 35% achieving PR. The median time to response was 48 days, median OS was 9.4 months, and PFS was 3.2 months.

A phase I trial combining palbociclib and ibrutinib in 27 patients with previously treated MCL demonstrated ibrutinib 560 mg daily plus palbociclib 100 mg on days 1–21 of a 28-day cycle could be safe. With a median follow-up of 256 months, ORR and CR were noted in 67% and 37%, respectively. Grade 3–4 toxicities including neutropenia were noted in 41% of the cohort, thrombocytopenia in 30%, hypertension in 15%, febrile neutropenia in 15%, and pulmonary infection in 11%.

Various combination therapeutic strategies incorporating ibrutinib, rituximab, bendamustine, and R-CHOP have significantly improved treatment response rates in both the naïve and refractory patients.[38-40] Rituximab with ibrutinib in a relapsed setting showed an ORR and CR of 88% and 44%, respectively. In a phase I/Ib study, the combination of bendamustine and rituximab showed ORR of 94% and CR of 76%, with AEs encompassing predominantly cytopenia and rash (25%). Finally, in the treatment naïve setting, the combination of ibrutinib with R-CHOP showed an ORR of 94% with only major grade 4 toxicity of neutropenia, although the study only included five patients.

In MANTLE-FIRST study, 261 patients with first R/R MCL after upfront high-dose cytarabine-containing regimens were recruited and analyzed.[19,42] OS and PFS were analyzed from the time of salvage therapy. Second-line regimens consisted of rituximab and bendamustine (RB, 21%); rituximab, bendamustine, and cytarabine (R-BAC, 29%); ibrutinib (19%); and others (31%). R-BAC induced a higher rate of CR (63%) than other second-line regimens. Improved median PFS was noted in the ibrutinib and R-BAC cohorts (24 and 25 months, respectively). In patients who developed early disease progression, ibrutinib was associated with improved outcomes than comparator regimens, which makes it the only available non-chemoimmunotherapy drug in the relapsed setting.

Another multicenter open-label single-arm phase II trial, PHILEMON, reported efficacy and safety of ibrutinib in combination with lenalidomide and rituximab in 50 patients with R/R MCL enrolled between 2015 and 2016. With a median follow-up of 17.8 months, 76% of patients had an ORR with CR and PR achieved in 56% and in 20%, respectively. The most prevalent grade 3–4 AEs were neutropenia (38%), infections (22%), and cutaneous toxicity (14%).

Another BTK inhibitor, acalabrutinib, is a highly selective and potent BTK inhibitor with limited off-target activity. A recent phase II study found an 81% ORR and 40% CR in the R/R setting. Besides its tolerance significantly better than ibrutinib, acalabrutinib also has a significantly better side effect profile with no increased grade 1–2 atrial fibrillation and bleeding events. An extended 26-month follow-up of the multicenter phase II ACE-LY-004 study of acalabrutinib 100 mg twice daily showed an ORR and CR of 81% and 43%, respectively. The estimated 24-month OS rate was 72.4%. Acalabrutinib was approved by the FDA for relapsed MCL second-line treatment in 2019.

More recently, another BTK inhibitor, zanubrutinib, has been approved by the FDA for the treatment of MCL patients who have received at least one prior treatment. Zanubrutinib is a selective, irreversible, second-generation BTK inhibitor developed in China. A multicenter phase II study (NCT03206970) of zanubrutinib (160 mg twice daily by mouth) in 86 patients with previously treated MCL reported 84% ORR (59% CR); the median duration of response was 19.5 months. A similar ORR was reported in another zanubrutinib study that included 32 patients with previously treated MCL (NCT02343120). The most common AEs (⩾20%) were cytopenia, rash, bruising, diarrhea, and cough. Headache, a side effect not commonly seen with other BTK inhibitors, was frequently reported and responded to caffeine.

ARQ-531 (nemtabrutinib), another novel BTK inhibitor in clinical trials, reversibly binds and inhibits the BTKs. This agent reportedly has activity in chronic lymphocytic leukemia (CLL) patients whose disease has progressed after ibrutinib treatment due to the BTK-C418 mutation, the most common mutation associated with resistance to BTK inhibitors. However, the BTK-C418 mutation is not commonly seen in MCL patients.

LOXO-305 (pirtobrutinib), a highly selective, non-covalent BTK inhibitor, is currently under investigation in a BRUIN phase I/II multicenter trial to define safety and efficacy in multiple B-cell malignancies, including MCL. As of April 2020, 186 patients, including 38 patients with MCL, had been enrolled. Among this cohort, 92% had previously received BTK inhibitor treatment. Of the 35 efficacy-evaluable MCL patients enrolled, ORR was 51% (9 patients with CR, 9 with PR, 7 with stable diease status [SD]). The study concluded that LOXO-305 poses a novel, promising therapeutic efficacy in heavily pretreated MCL patients with poor prognosis.

Orelabrutinib, which is a potent, irreversible, and highly selective BTK inhibitor, has been approved in China for the treatment of patients with MCL who have received at least one treatment in the past. Clinical studies are underway in the United States in evaluating orelabrutinib efficacy, safety, and indication.

Lenalidomide and other immunomodulatory drugs

Lenalidomide is an antineoplastic agent with immunomodulatory capabilities. The ORR of R/R MCL to lenalidomide monotherapy was reported to be 28–57% and CR of 7.5–36%, with median PFS ranging from 4 to 5.7 months.[51-53] However, in a study combining lenalidomide and bortezomib to treat relapsed MCL, there were issues related to toxicity-related dose reduction and inadequate treatment dosing.

In the relapsed setting, a combination of lenalidomide with rituximab showed some improvement in both median PFS and OS (11.1 and 24.3 months, respectively). This combination therapy achieved an excellent response in induction, maintenance (ORR: 92%), and in the first-line setting (CR: 64%), with 50% of patients experiencing grade 3 or 4 neutropenia and 29% of patients with grade 3 or 4 rashes. Unfortunately, utilizing lenalidomide predisposes patients to treatment-related cancers, commonly non-invasive skin cancers, and more rarely, Merkel cell carcinoma and pancreatic cancer.

The use of lenalidomide and rituximab in a first-line setting is still under investigation. Ruan et al. described a 5-year follow-up of phase II study of lenalidomide plus rituximab as initial treatment of 36 evaluable MCL patients. With a median follow-up period of 64 months, the OS rates were 89.5% and 77.4% at 3 and 5 years, respectively. Eight of 10 patients who had completed 3 or more years of treatment achieved MRD-negative CR. This study indicates that combination therapy of lenalidomide and rituximab as the first-line treatment could achieve a durable response with limited toxicity. At 2021 american society of hematology (ASH) meeting, Ribrag et al. reported the results from the MCL R2 elderly clinical trial that Rituximab-Lenalidomide Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma.

The efficacy of combination therapy using bendamustine, lenalidomide, and rituximab in a first-line setting was studied in elderly patients with a median age of 72. BR was used as the induction therapy with 52 weeks of lenalidomide maintenance. Post induction therapy, 64% of patients reached CR and 36% were MRD negative, with median PFS and OS of 42 and 53 months, respectively, with a median follow-up of 31 months. The main shortfall of this study was a high incidence of serious infections, which indicates that this combination therapy may not fit well for the elderly population that this therapeutic strategy is intended for. Thus, while lenalidomide provides a promising avenue, further studies to evaluate the efficacy of combination therapies are required. Optimizing the treatment dosage and the duration will be essential before transitioning lenalidomide into a first-line treatment setting.

Other molecules structurally related to lenalidomide are also under investigation. Pomalidamide (CC-4047) has been FDA approved for the treatment of multiple myeloma and is being studied in other hematologic malignancies. Other similar immunomodulatory drugs/molecules (IMIDS), such as CC-220 (NCT03161483) and CC99282 (NCT04434196), showed additional immunomodulatory and immunostimulatory features in vitro and are in NHL clinical trials.

A single-center phase II study evaluating frontline sequential immunotherapy plus lenalidomide for MCL was recently explored. The median follow-up duration was 2.8 years, and the 3-year PFS and OS were 64% and 85%, respectively. Among 47 patients evaluable for PFS enrolled in the trial, 45 completed maintenance, 43 achieved CR, and 1 was at stable disease status at the end of treatment with an ORR of 91%.

Venetoclax

Venetoclax is a BCL-2 inhibitor that was FDA approved for the treatment of CLL and acute myeloid leukemia (AML). In a phase I study, venetoclax showed activity against relapsed MCL with the single-agent activity of 75% and a median duration of response of 15.7 months. The response to MCL patients who had failed ibrutinib therapy was lower, about 40–50%. The data regarding ibrutinib and venetoclax combination therapy were updated during the 2019 ASH annual meeting. In that study, the CR rates reached to 62% and the median PFS was 29 months. MRD-negative remissions were also reported, and several patients discontinued treatment without evidence of progression. Recently, a multicenter prospective phase I/II trial found that the combination of ibrutinib, obinutuzumab, and venetoclax had no dose-limiting toxicity. Meanwhile, this combination therapy reached the CR rates of 67% by cycle 6 in relapsed MCL patients and 86.6% in untreated patients with a 2-year PFS of 69.5%. Further data on this combination are pending.

Data from a recent Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I trial included 16 R/R MCL patients evaluable for efficacy who received venetoclax, lenalidomide, and rituximab. In this study, ORR was noted to be 56%, with five patients achieving CR and four patients achieving PR. Four patients discontinued treatment after achieving molecular remission. Although the follow-up period was short, this study indicates that patients who achieved molecular remission could stop treatment under close monitoring.

mTOR and PI3K inhibitors

Mammalian target of rapamycin (mTOR) and phosphatidylinositol 3-kinase inhibitors such as rapamycin (sirolimus) and idelalisib have long been investigated. However, only in the most recent decade, these classes of molecules emerged in various clinical studies ranging from rheumatology to transplantation and to oncology largely due to its central role in metabolism modulation. mTOR inhibitors work by impairing lymphocyte activation and proliferation in response to antigenic and cytokine stimulation. In cells, sirolimus binds to FK Binding Protein-12 (FKBP12) to generate an immunosuppressive complex. This complex then binds to and inhibits mTOR activation, suppressing cytokine-driven T-cell proliferation by inhibiting cell cycle progression from G1 to S phase.

Temsirolimus, a prodrug of sirolimus, has been evaluated in multiple settings of MCL treatment. In a phase III randomized controlled trial in R/R MCL patients, temsirolimus was tested at two dosages compared with the investigator’s choice. It was found that the cohort that received two dosages had better objective response rates (22%) than the investigator’s choice cohort (2%). The PFS in temsirolimus arm was also improved to 4.8 months, although OS in each arm was not statistically significant. Temsirolimus monotherapy with alternative dose adjustments has been tested and demonstrated notable improvement in both ORR (38–41%) and median OS (12 months).[68,69] Temsirolimus in combination with bendamustine and rituximab showed safe and effective in treating MCL in refractory settings. Unfortunately, other mTOR inhibitors, such as everolimus, had limited success with an ORR of 8.6% (all partial responses). Similarly, median PFS and median OS were not improved (4.4 and 16.9 months, respectively). The results of temsirolimus combined with cladribine and another active agent in a phase I/II MCL study were reported as well.

At 2020 ASH, parsaclisib, a next-generation oral phosphoinositide 3-kinas (PI3K) inhibitor, was reported to result in a high rate of rapid and durable responses in refractory NHL, including MCL (NCT03235544).[73,74]

Epigenetic agents

Since epigenetic deregulation of cyclin D1 is involved in molecular pathogenesis, epigenetic or cell cycle targeted therapies potentially offer precision medicine approaches. The molecular mechanisms involved remain to be elucidated, but some epigenetic agents have been investigated in MCL treatment. Epigenetics has become an important factor in MCL disease development. Vorinostat, a pan histone deacetylase (HDAC) inhibitor, has shown promising results with data suggesting that it possesses a less toxic profile and could be combined with rituximab to be clinically efficacious. Vorinostat is FDA approved for the treatment of cutaneous T-cell lymphoma. DNA hypomethylating agents such as 5-azacytidine or decitabine have shown limited activity and are toxic in MCL and other B-cell lymphomas. However, cladribine, but not fludarabine, is a cryptic hypomethylating agent that inhibits DNA, RNA, and histone methylation by inhibiting s-adenosyl methionine (SAM), the donor of methyl groups. In MCL, cladribine has been shown to have activity as a single agent that is synergistic with rituximab.[78,79] Cladribine was originally FDA approved for hairy cell leukemia treatment. In a phase II trial of 80 MCL patients treated with cladribine alone and in combination with rituximab, a durable CR was observed in about 50–60% of newly diagnosed patients. The addition of vorinostat to cladribine and rituximab resulted in a 97% response rate in a phase II trial, with CR obtained in about 80% of patients. Some of these responses are extremely durable, with patients on trial now than 10 years in remission, which suggests that this regimen may be curative. Another phase I study using bortezomib, cladribine, and rituximab (VCR) combination showed impressive result as well. The ability of immuno- and epigenetic combination therapy to achieve long-term durable remissions is surprising, in contrast to conventional chemotherapy with maintenance or high-dose therapy/ASCT with maintenance. Further study is warranted.

In June 2020, the EZH2 histone methyl transferase (HMT) inhibitor, tazemetostat, was approved by FDA to treat EZH2 gene mutated and treatment-refractory follicular lymphoma. This molecule also has preclinical activity to MCL and is incorporated into MCL clinical trial now (NCT03456726). Other EZH2 and HMT inhibitors are in preclinical and clinical development. EZH2 gene mutations are uncommon in MCL, but a deregulated expression of EZH2 and chromodomain-containing proteins, such as EED and SUZ12, has been reported in MCL.

Monoclonal antibodies and antibody-drug conjugates

Currently, there are no FDA-approved monoclonal antibodies or antibody-drug conjugates (ADCs) for MCL. Anti-CD20 antibodies rituximab and obinutuzimab are FDA approved for other types of NHL and are frequently used in MCL, usually in combination. Other monoclonal antibodies and ADC in development for MCL are polatuzumab vedotin (CD79a; FDA approved for diffuse large B-cell lymphoma, DLBCL) and ublituximab, a glyco-engineered anti-CD20 antibody.

In addition, VLS-101 (zilovertamab), a ROR1 (receptor tyrosine kinase-like Orphan Receptor 1)-targeting ADC, showed efficacy in the first-in-human phase I study evaluating the efficacy and safety of the drug in 32 heavily pretreated MCL (15 patients) and DLBCL patients. Objective tumor response was noted in seven patients with MCL (four PR and three CR).

As aforementioned, some monoclonal antibodies such as rituximab and obinutuzumab and small molecules such as venetoclax have been used for MCL maintenance therapy. Still, the exact duration and type of maintenance therapy remain to be optimized. Some MCL specialists continue maintenance therapy until progression, while others use a fixed 2-year, 3-year, or 5-year schedule.

Allogeneic stem cell transplant

Allogeneic stem cell transplant (allo-SCT) remains the only known and well-studied curative option for younger patients with limited comorbidities. Donor availability has largely been overcome using matched unrelated, cord blood, and haploidentical transplant approaches coupled with post-transplant cyclophosphamide to reduce graft versus host disease. However, this approach remains limited by preexisting comorbidities and complications such as graft versus host disease despite advances in allo-SCT. Allo-SCT employs graft-versus-leukemia effect to provide a durable disease clearance in patients with R/R MCL[87,88] A recent study conducted by the European Bone Marrow Transplant Chronic Malignancies and Lymphoma Working Parties included 70 patients (48 with CLL and 22 with MCL) who were bridged to allo-SCT from ibrutinib. At the time of transplant, 73% of patients were responsive to ibrutinib. In the MCL cohort, the 12-month non-relapse morality, PFS, and OS were 5%, 76%, and 86%, respectively. This study demonstrates that patients with ibrutinib-sensitive R/R MCL had an excellent disease control with allo-SCT. Ibrutinib may be a promising consolidation regimen for ibrutinib-sensitive MCL prior allo-SCT. In a recent retrospective MANTLE-FIRST study, 55 patients underwent allo-SCT for R/R MCL after treating with rituximab and high-dose cytarabine; the patients using BTK inhibitor as a bridge to allo-SCT achieved good disease control without an increase in toxicity.

CAR-T cell therapy and BiTE therapy

CAR-T cell therapy has revolutionized the field of immunotherapy. Three CD19 products are currently FDA approved for relapsed DLBCL (axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel)[91,92] and one (tisagenlecleucel) approved for refractory B-cell acute lymphocytic leukemia (ALL). A CD19 (KTE-C19; brexucabtagene autoleucel) CAR-T product recently received FDA approval for the treatment of R/R MCL. A 93% response rate with a 67% CR rate was reported. However, concerns pertaining to the cost and accessibility of brexucabtagene autoleucel are emerging, similar to other approved CAR-T cell therapies.

BiTE therapy is a unique strategy that engages the cytotoxicity of T cells against cancer sites. BiTEs are fusion proteins consisting of an element that binds the CD3 receptors and the other to a tumor cell via a tumor-specific molecule. The mainstay of this class of drugs is blinatumomab, a bispecific CD19/CD3 antibody. In a phase I trial involving 24 MCL patients in the NHL cohort, blinatumomab demonstrated an ORR of 71%. In a follow-up study of this cohort for long-term survival, median OS of 1560 days and median PFS of 204 days were noted. More recently, mosunetuzumab, a bispecific CD20/CD3 T-cell engager, was developed and trialed in a phase I study presented in the 2018 ASH meeting that showed promising efficacy and safety with favorable response outcomes in patients who were thought to be refractory to anti-CD20 therapy. However, limited data are available for mosunetuzumab as trials are currently underway. At 2021 ASH meeting, the early data from another bispecific CD20/CD3 T-cell engager, glofitamab, were presented. The data demonstrated that glofitamab step-up dosing (SUD) as monotherapy after glofitamab with obintuzumab pretreatment (Gpt) induced high response rates in patients with MCL (ORR: 81%, CR: 66.7%), most of whom had failed prior BTKi therapy. The cytokine release syndrome (CRS) rates were manageable and mostly low grade. Immune effector cell-associated neurotoxicity syndrome (ICANS)-like AEs were infrequent, low grade, and resolved within 1 day. No treatment discontinuations due to AEs were observed.

Young patients and TP53 mutation

While MCL is a disease that predominantly impacts elderly patients with the median age of diagnosis between 60 and 70 years of age, a significant proportion of MCL patients are young individuals. Younger patients are generally treated differently because of their age and performance status. Young patients can tolerate high-dose cytarabine-based regimens, which can be subsequently followed by ASCT. Studies from both French and North American groups found a considerable improvement in PFS when ASCT is followed by rituximab maintenance.[99,100] More recently, a phase I/II trial demonstrated the efficacy of CpG-activated tumor cells in ASCT that amplified a CD8+ T-cell immune response, consequently resulting in a superior clinical outcome. Historically, therapies have been directed at subgroups of young fit patients with limited comorbidities compared with older patients with significant comorbidities. For young fit SCT eligible patients who achieved a complete or partial response, high-dose chemotherapy with or without autologous stem cell rescue still remains a trending option. Autologous stem cell rescue is commonly used but is not curable and ineffective in high-risk patients with blastoid variant MCL. A randomized head-to-head trial will ultimately suggest the best approach.

A TP53 mutation has also been recently recognized as a very poor prognostic marker. One study found that patients harboring a specific TP53 mutation had inferior treatment outcomes. One proposed solution to overcome this unfavorable prognostic feature is the implementation of allo-SCTs instead of the standard ASCT approach. Agents active in TP53 mutated MCL are currently under investigation. In addition, agents specifically capable of refolding P53 molecules in hematologic malignancies are also under evaluation.

Conclusion

In summary, MCL is a group of heterogeneous B-cell lymphomas harboring unique pathological characteristics. However, its heterogeneity in both disease presentation and response to therapy have made this entity a challenge for the oncology community. Aside from the aforementioned novel agents, many potentially promising new molecules and treatment approaches continuously emerge through the clinical trial pipeline (Table 2). With the advent of highly active novel agent combinations, new therapeutic modalities, and more targeted prognostic factors, there will be a need to personalize the therapies in the future. With the advent of whole-genome and transcriptome sequencing at both DNA and RNA levels, the scientific community is able to screen genetic profiling for prognostic factors. Furthermore, MRD has also been used as treatment outcome predictions, with findings that MRD positivity is highly predictive of shorter OS. With such rapid advances in scientific discovery and innovative technology developments, the future is promising for curing MCL.

Table 2.

The ongoing clinical trials investigate promising new molecules and innovative therapeutic approaches.

Name of molecule	Category	Trial phase	Target/mechanism	ClinicalTrials.gov identifier
Tisagenlecleucel	CAR-T (CD19)	II	CD19	NCT04234061
	CAR-T (CD19)	I, II	CD19	NCT03676504
TC-110	TCR fusion construction	I, II	CD19-CD3	NCT04323657
Epcoritamab	BiTE therapy	I, II	CD3 × CD20	NCT03625037
Obinutuzumab	Biologics	II	Anti-CD20	NCT02736617
Obinutuzumab	Biologics	II	Anti-CD20	NCT03229382
Ublituximab	Biologics	III, IV	Anti-CD20	NCT02793583
Palbociclib	CDK inhibitor	II	CDK4/6	NCT03478514
Parsaclisib	PI3K inhibitor	II	PI3K α/δ	NCT03235544
LOXO-305	BTK inhibitor	I, II	BTK	NCT03740529
Orelabrutinib	BTK inhibitor	II	BTK	NCT05076097
Chidamide	Histone deacetylation inhibitor	II	HDAC1/2/3/10	NCT03629873
ONC201	Akt/ERK inhibitor	I, II	Akt/ERK	NCT02420795
TQ-B3525	PI3K inhibitor	II	PI3K α/δ	NCT04398953
Parsaclisib	PI3K inhibitor	II	PI3K α/δ	NCT03235544
BGB-10188	PI3K inhibitor	I, II	PI3K α/δ	NCT04282018
CLR 131	Radioiodinated therapeutic	II	Cytotoxic radioisotope	NCT02952508
SNS-062	BTK/ITK inhibitor	I, II	BTK/ITK	NCT03037645
CYT-0851	RAD51 inhibitor	I, II	Inhibition of cytidine deaminases and DNA repair	NCT03997968
Pembrolizumab	PD-1 antibody	II	Blocking PD-L1 and PD-L2 from interacting with PD-1	NCT03153202
NVG-111	BiTE	II	Binding to ROR1/CD3	NCT04763083
TL-895	ITK inhibitor	II	Blocking tyrosine kinase	NCT02825836
IGM-2323	An engineered bispecific IgM antibody	I	Block CD20	NCT04082936
BP1002	L-Bcl-2 antisense oligonucleotide	I	Suppressing L-Bcl-2	NCT04072458

BiTE, bispecific T-cell engager; BTK, Bruton’s tyrosine kinase; CAR-T, chimeric antigen receptor-T cell; ITK, irreversible tyrosine kinase; ROR1, receptor tyrosine kinase-like Orphan Receptor 1 ; TCR, T cell receptor; PD-1, program death-1.